BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

GlaxoSmithKline (GSK) Stops Tykerb Arm of Breast-Cancer Trial


9/12/2011 7:45:27 AM

LONDON (MarketWatch) -- GlaxoSmithKline PLC /quotes/zigman/146635/quotes/nls/gsk GSK -1.83% Friday said it will stop administering breast cancer drug Tykerb alone to patients in a clinical trial, after an independent committee decided the medicine would probably produce worse results than Roche Holding AG's (ROG.VX) rival product Herceptin.

The three arms of the late-stage trial in which patients take Tykerb in combination with Herceptin, or trastuzamab, will continue as planned, GSK said in a statement.

"The committee has indicated that the lapatinib-alone arm is unlikely to meet the pre-specified criteria to demonstrate non-inferiority to trastuzumab alone with respect to disease-free survival."

"Consequent to this finding, patients assigned to the lapatinib-alone arm of the trial will discontinue lapatinib and discuss treatment options with their study physician."

The trial, known as ALTTO, is a randomized, multi-center, Phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2-positive primary breast cancer--an aggressive form of the disease--GSK said.



Read at Reuters
Read at BioSpace.com
Read at News Release

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES